Page last updated: 2024-11-12
segetalin b
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
segetalin B: isolated from Vaccaria segetalis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Vaccaria | genus | A plant genus of the family CARYOPHYLLACEAE. The common name Soapwort is also used with SAPONARIA.[MeSH] | Caryophyllaceae | A plant family of the order Caryophyllales, subclass Caryophyllidae, class Magnoliopsida. The species are diverse in appearance and habitat; most have swollen leaf and stem joints.[MeSH] |
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10345235 |
| CHEMBL ID | 386632 |
| SCHEMBL ID | 151686 |
| MeSH ID | M0267180 |
Synonyms (11)
| Synonym |
|---|
| segetalin b |
| CHEMBL386632 |
| SCHEMBL151686 |
| 164991-89-3 |
| segetalin-b |
| (3s,6s,9s,12s)-6-(1h-indol-3-ylmethyl)-3,9-dimethyl-12-propan-2-yl-1,4,7,10,13-pentazacyclopentadecane-2,5,8,11,14-pentone |
| MS-29005 |
| HY-107245 |
| E88615 |
| CS-0027753 |
| AKOS040760076 |
Research Excerpts
Overview
Segetalin B (SB) is a cyclic peptide compound showing estrogenic activity.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Segetalin B (SB) is a cyclic peptide compound showing estrogenic activity." | ( SIRT1/Notch1 signal axis involves in the promoting effect of Segetalin B on bone formation. Cheng, Q; Lan, X; Luo, J; Ma, H; Xiao, Y; Yuan, Z; Zou, L, 2022) | 1.68 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID270574 | Vasocontractile effect on norepinephrine-induced contraction of rat thoracic aortic ring without endothelium at 100 uM | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Structure of a new cyclic nonapeptide, segetalin F, and vasorelaxant activity of segetalins from Vaccaria segetalis. |
| AID270572 | Vasocontractile effect on norepinephrine-induced contraction of rat thoracic aortic ring with endothelium at 100 uM | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Structure of a new cyclic nonapeptide, segetalin F, and vasorelaxant activity of segetalins from Vaccaria segetalis. |
| AID270571 | Vasorelaxation effect against norepinephrine-induced contraction of rat thoracic aortic ring with endothelium at 100 uM | 2006 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17 | Structure of a new cyclic nonapeptide, segetalin F, and vasorelaxant activity of segetalins from Vaccaria segetalis. |
| AID402827 | Estrogen-like activity in ovariectomized SD rat assessed as increase in uterus weight at 2.5 mg/kg, sc administered daily for 14 days | 1997 | Journal of natural products, Mar, Volume: 60, Issue:3 | Cyclic peptides from higher plants. 34. Segetalins G and H, structures and estrogen-like activity of cyclic pentapeptides from Vaccaria segetalis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.77
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.77) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||